Evogliptin: First Global Approval

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

(2015) Xiao-Wu Chen et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

(2014) Chang Hee Jung et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

(2014) Namyi Gu et al.   Drug Design Development and Therapy

Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human Study

(2012) Tae-Eun Kim et al.   CLINICAL THERAPEUTICS

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

(2011) Heung Jae Kim et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes

(2011) Mi-Kyung Kim et al.   LIFE SCIENCES

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

(2010) Jae Min Cho et al.   DIABETES RESEARCH AND CLINICAL PRACTICE